# **Special Issue**

# Development of Bone Targeted Drug Delivery Technologies

## Message from the Guest Editor

The skeleton provides support and structure to the body. As people age, they start to lose their cartilage and bone mass. The current therapeutic strategy for degenerative spine, bone or joint diseases is focused on reducing pain and minimizing structural and symptomatic progression in order to delay surgery therapy as long as possible. There is no cure for these bone diseases, and hence, tissue engineering, cell therapy, and local drug delivery may provide more effective therapeutics. Until now, bone-targeted drug delivery technologies have tended to focus on local delivery systems. At present, we are particularly taking an interest in manuscripts that report bone-targeted drug delivery systems and which can efficiently bring drugs (or cells) to bone or cartilage tissues. Main topics include but are not limited to:

- Cell therapy in spine, bone, and cartilage;
- The application of tissue engineering in spine, bone, and cartilage;
- Drug delivery in spine, bone, and cartilage.

## **Guest Editor**

Prof. Dr. Hsin-I. Chang

Department of Biochemical Science and Technology, National Chia Yi University, No. 300, Syuefu Rd, Chiayi City 60004, Taiwan

## Deadline for manuscript submissions

closed (30 September 2022)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/100954

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

